Hospital perspective of shortages casts pharma earnings in bad light

Editor Ron Shinkman at sister publication FierceHealthFinance looks at drug shortages from the hospital exec's perspective and doesn't especially like what he sees. He finds that some shortages are caused by factory shutdowns. But unlike most other businesses in which shutdowns can lead to devastating write-offs, he instead finds companies revising operating and net income upward. Among his examples: Daiichi Sankyo's ($4568) American Regent, Hospira ($HSP), Boehringer Ingelheim's Bedford Labs and Bristol-Myers Squibb ($BMY). Editorial